Parkinson's News Today Home | Parkinson's News Today
WEBNew method may identify younger people at risk for Parkinson’s. A new method for detecting toxic protein clumps of alpha-synuclein in skin cells may help diagnose Parkinson’s disease up to two decades before motor symptoms appear, according to a …
New Vaccine for Parkinson’s Moves Closer to 1st Human Trials
WEBDec 1, 2022 · An experimental vaccine that stimulates immune responses against three regions of the alpha-synuclein protein — whose toxic clumps contribute to Parkinson’s disease and dementia with Lewy bodies (DLB) — is moving into late-stage preclinical research aimed at supporting future requests to test it in clinical trials.
News Archives - Parkinson's News Today
WEBNew method may identify younger people at risk for Parkinson’s. A new method for detecting toxic protein clumps of alpha-synuclein in skin cells may help diagnose Parkinson’s disease up to two decades before motor symptoms appear, according to a …
Top 10 Parkinson’s Disease Stories of 2022 - Parkinson's News Today
WEBDec 29, 2022 · The top 10 Parkinson's News Today stories published in 2022 focused on symptoms, treatments, and risk factors in the progressive disease.
Risvodetinib may slow Parkinson's progression, clinical trial...
WEBMar 11, 2024 · Risvodetinib, an oral therapy being developed by Inhibikase Therapeutics for Parkinson’s disease, appears to stabilize disease status and severity, according to data covering 25 patients who finished 12 weeks of dosing in an ongoing Phase 2 clinical trial.
FDA clears Phase 1/2a trial of stem cell therapy for Parkinson's...
WEBAug 9, 2023 · The U.S. Food and Drug Administration (FDA) has given Aspen Neuroscience clearance to launch a clinical trial of ANPD001, an experimental stem cell therapy designed to replace the nerve cells that are lost in Parkinson’s disease.
Parkinson's vaccine seen to target toxic protein in Phase 1 trial
WEBMar 11, 2024 · Treatment with UB-312, a vaccine designed to trigger an immune response against toxic clumps of the alpha-synuclein protein, reduced these damaging aggregations in people with Parkinson’s disease in a Phase 1 trial.
AAN 2024: Prasinezumab may slow Parkinson's motor symptoms
WEBApr 18, 2024 · Treatment with prasinezumab — an experimental therapy designed to stop toxic alpha-synuclein protein clumps from spreading through the brain — seems to slow the progression of motor symptoms in people with Parkinson’s disease.
Trial of buntanetap for early-stage Parkinson’s nears end
WEBDec 7, 2023 · In this Phase 3 trial patients with early-stage Parkinson’s, ages 40 to 85, were assigned randomly to receive one capsule of either 10 or 20 mg of buntanetap, or a placebo, once daily for six months. The treatment was given in …
Phase 3 trials of tavapadon for Parkinson's motor symptoms near …
WEBNov 7, 2023 · An ongoing and global Phase 3 clinical trial program for oral tavapadon, a selective dopamine receptor agonist aiming to improve motor function in people with Parkinson’s disease, expects to release study findings next year.
Skip to content